193 results on '"Freedland, Stephen"'
Search Results
2. Dietary Fiber Intake and Risk of Advanced and Aggressive Forms of Prostate Cancer: A Pooled Analysis of 15 Prospective Cohort Studies
3. COMPARING WHITE LIGHT VERSUS BLUE LIGHT CYSTOSCOPY RECURRENCE OUTCOMES AMONG NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS IN AN EQUAL ACCESS SETTING: A PROPENSITY SCORED MATCHED ANALYSIS
4. Contemporary risk of biochemical recurrence after radical prostatectomy in the active surveillance era
5. LONGITUDINAL CHANGES IN PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH HIGH-RISK BIOCHEMICALLY RECURRENT (BCR) NONMETASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) FROM THE EMBARK STUDY
6. The Impact of Blue Light Cystoscopy Use Among Nonmuscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence
7. The impact of life expectancy on cost-effectiveness of treatment options for clinically localized prostate cancer
8. Prostate-Specific Antigen Screening in Transgender Patients
9. Reply to Sandra Patricia García Nader, Sebastián Peña Rodríguez, and Cesar Alejandro Diaz Ritter’s Letter to the Editor re: Farnoosh Nik-Ahd, Andrew Jarjour, Jane Figueiredo, et al. Prostate-specific Antigen Screening in Transgender Patients. Eur Urol. 2023;83:48–54
10. Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
11. The 17-Gene Genomic Prostate Score Test Is Prognostic for Outcomes After Primary External Beam Radiation Therapy in Men With Clinically Localized Prostate Cancer
12. The 24-Hour Movement Paradigm: An integrated approach to the measurement and promotion of daily activity in cancer clinical trials
13. Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma
14. Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients
15. Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort
16. Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race
17. Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer
18. Demographic Differences and Disparities in the Misdiagnosis of Interstitial Cystitis/Bladder Pain Syndrome in a National Cohort of VA Patients
19. Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer
20. Red Blood Cell Distribution Width Is Associated with All-cause Mortality but Not Adverse Cancer-specific Outcomes in Men with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy: Findings Based on a Multicenter Shared Equal Access Regional Cancer Hospital Registry
21. Non-canonical role of Hippo tumor suppressor serine/threonine kinase 3 STK3 in prostate cancer
22. Epidemiology and Prevention of Prostate Cancer
23. Diagnostic Utility of Serum and Urinary Metabolite Analysis in Patients with Interstitial Cystitis/Painful Bladder Syndrome
24. Comorbidities in a Nationwide, Heterogenous Population of Veterans with Interstitial Cystitis/Bladder Pain Syndrome
25. Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy
26. Patients’ preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation
27. A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer
28. Do Hispanic Men Have Worse Outcomes After Radical Prostatectomy? Results From SEARCH
29. Use of Chemotherapy and Androgen Signaling–targeted Inhibitors in Patients with Metastatic Prostate Cancer
30. Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?
31. Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer
32. Impact of Alzheimer's disease and related dementia diagnosis following treatment for bladder cancer
33. Impact of Diagnosing Urologists and Hospitals on the Use of Radical Cystectomy
34. Low Carbohydrate Diets in Men with Prostate Cancer May Reduce Risk of Cardiovascular Disease
35. WALNUTS for POWER: A Protocol for the Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Randomized Controlled Trial
36. Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy
37. Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy
38. Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?
39. Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer
40. Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients
41. Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH
42. An update of research evidence on nutrition and prostate cancer
43. A Low Glycemic Index Diet Slows Prostate Cancer Growth (P05-018-19)
44. Blood and dietary magnesium levels are not linked with lower prostate cancer risk in black or white men
45. Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database
46. Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database
47. Rapid Next-Generation Sequencing Method for Prediction of Prostate Cancer Risks
48. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
49. Statin Therapy to Improve Prostate Cancer Outcomes: Who, When, and for How Long?
50. A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.